Fondazione Policlinico Universitario A. Gemelli, IRCCS
Rome, 00168, Italy
Location status: Recruiting
NCT Number: NCT06398938
To evaluate the degree of acute and long-term intestinal, urinary and vaginal toxicity, and the impact on sexual activity of an accelerated fractionation of high dose rate interventional radiotherapy (IRT-HDR) in patients with locally advanced cervical cancer (IB2 - VA, N+/-).
Interested in participating?
Request Info18 year and older
Female
Observational
Rome, 00168, Italy
Location status: Recruiting
Observational, monocentric and prospective study. All patients with locally advanced cervix cancer will be underwent to radiochemotherapy followed by accelerated interventional radiotherapy (brachytherapy). Fist endpoints wer severe acute and late gastrointestinal, and urinary toxicities and sexual activity.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patients will undergo four IRT fractions in one week
Time frame: 6 months
Acute and late toxicities will evaluated with CTCAE scale to analyze the safety of accelerated interventional radiotherapy
Time frame: 6 months
Acute and late urinary toxicities will evaluated with CTCAE scale to analyze the safety of accelerated interventional radiotherapy
Time frame: 6 months
Sexual activity will evaluated with CTCAE scale to analyze the safety of accelerated interventional radiotherapy
Contact information is provided by the study sponsor or research team.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
EROS 3 Study Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy Brachytherapy in Terms of Overall Toxicity and Sexual Activity
Acronym: EROS3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06529809
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
St Louis, Missouri, United States
View Trial DetailsNCT05269381
Adenocarcinoma, Anatomic Stage III Breast Cancer AJCC v8
Jacksonville, Florida, United States
View Trial DetailsNCT05975593
Cancer of the Cervix, Cancer of the Pancreas
St Louis, Missouri, United States
View Trial DetailsNCT05406856
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Leiden, Netherlands
View Trial Details